SCHEMBL4513347

SCHEMBL4513347

C[C@@H](COc1cccc2ncccc12)NS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)n(C)n2)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 12/20 0.55
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
PTGES2 Q9H7Z7 1/20 0.47
POLB P06746 1/20 0.40
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
S1PR4 O95977 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
S1PR1 P21453 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4516667 0.86 NR3C1 (0.56) NR3C1GAAL3MBTL1PTGES2POLB
SCHEMBL4520609 0.82 GAA (0.53) GAAL3MBTL1PTGES2POLBALDH1A1
SCHEMBL4520346 0.77 NR3C1 (0.67) NR3C1GAAL3MBTL1ALDH1A1MEN1
SCHEMBL4516700 0.75 NR3C1 (0.62) NR3C1L3MBTL1ALDH1A1MEN1S1PR4
SCHEMBL4559868 0.72 GAA (0.43) GAAL3MBTL1PTGES2POLBTP53
SCHEMBL4782481 0.72 NR3C1 (0.61) NR3C1GAAL3MBTL1PTGES2
SCHEMBL4516862 0.72 NR3C1 (1.00) NR3C1
SCHEMBL13633881 0.71 PTGES2 (0.66) GAAL3MBTL1PTGES2MEN1KMT2A
SCHEMBL4501700 0.71 NR3C1 (1.00) NR3C1
SCHEMBL4517669 0.71 NR3C1 (0.73) NR3C1POLBALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885GAA 3779/4885L3MBTL1 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.